Cell & Gene Therapy World 2017

Optional sessions at Phacilitate Leaders Forum

Sign up today to make the most of your conference ticket! 

Please note:
- Only available to registered conference delegates
- Limited availability - first come first served!

phacilitate leaders optional session

Go straight to the form

 

Day 1 - Tuesday

Optional Breakfast Briefing with Oxford BioMedica

oxford biomedica
07:45am - 08:45am, Tuesday 23rd January
(Maximum 50 attendees)

Unique properties of lentiviral vectors for in vivo gene therapy programs

Presentations:
- Lentiviral vector based in vivo gene therapy for the treatment of hemophilia
- Clinical experience of lentiviral vectors in CNS: Parkinson’s Gene Therapy


Chair: Dr Jason Slingsby, Head of Business Development, Oxford BioMedica
Speakers:
Dr Tongyao Liu, Principal Scientist, Bioverativ, Inc
Dr James Miskin, Chief Technical Officer, Oxford BioMedica

Lunch Briefing sponsored by TerumoBCT

terumobct

1:00pm - 2:00pm, Tuesday 23rd January
(Maximum 50 attendees)


The Influence of the Apheresis Product on CAR T-cell Manufacturing


Speakers: 
Laura Connelly-Smith,
MBBCh,DM, Assistant Medical Director Apheresis and Cellular Therapy, SCCA; Assistant Professor, Division of Hematology, UW; Assistant Member, FHCRC, Seattle Cancer Care Alliance
Anand Padmanabhan, MD, PhD, QIA, Medical Director, Blood Center of Wisconsin; Associate Professor, Medical College of Wisconsin; Associate Investigator, Blood Research Institute

Roundtable with NDA Advisory Services

NDA

1:00pm - 2:00pm, Tuesday 23rd January
(Maximum 15 attendees)

Safety aspects of genetically modified cells

  • Product design
  • New modification tools
  • Insertional mutagenesis
  • RCR testing


Moderator: Dr Paula Salmikangas, Director for Biopharmaceuticals & ATMPs - NDA Advisory Services
 

Roundtable discussion with Paragon

paragon
1:00pm - 2:00pm, Tuesday 23rd January
(Maximum 15 attendees)

Discussion of the major AAV manufacturing platforms

 

Moderator: Sybil Danby, Director of Business Development, Paragon Bioservices, Inc

Roundtable discussion with time:matters

timematters
1:00pm - 2:00pm, Tuesday 23rd January
(Maximum 15 attendees)

Sketch your ideal cell & gene therapy logistics supply chain: high performance vein-to-vein process with maximum control


Moderator: Lars Krosch, Vice President Sales, time:matters

Roundtable discussion

fact

1:00pm - 2:00pm, Tuesday 23rd January
(Maximum 15 attendees)

How can FACT standards and accreditation help advance cellular therapies for regenerative medicine? 
FACT Standards and accreditation have historically played a role in the growth of and access to cellular therapies. Participants in this session will discuss how FACT can advance cellular therapies for regenerative medicine, drawing upon recent experience with immune effector cells (such as CAR-T products) as a case study.


Moderator: Patrick J. Hanley, PhD, Laboratory Facility Director, Cellular Therapy and Stem Cell Processing, Assistant Professor of Pediatrics, Children's National Health System, The George Washington University

Roundtable discussion with Cognate BioServices

cognate optional session phacilitate

1:00pm - 2:00pm, Tuesday 23rd January
(Maximum 15 attendees)

What today’s cell therapy companies need from a CDMO – a look at what, why and how a CDMO meets their client’s needs


Moderator: J. Kelly Ganjei, Chief Executive Officer, Cognate BioServices, Inc.

Day 2 - Wednesday

Breakfast Briefing with Invetech 

invetech
7:30am - 8:45am, Wednesday 24th January 
(Maximum 100 attendees)

Exploring the value of proprietary platforms in progressing your therapy
This is your opportunity to participate in a lively discussion around the value of developing proprietary manufacturing platforms and exploring alternative approaches.
We have assembled a distinguished panel of industry experts and opinion leaders to explore and discuss approaches and challenges. Our aim for this breakfast event is to enable you to prioritize your thinking and provide you with the some of the tools and insight that can assist you in the transition from clinical scale to commercial scale manufacturing.


Chair: Brian Hanrahan, Manager, Cell Therapy - Invetech
Speakers: 
Kim Warren, PhD, Head of Operations - AvroBio Inc.
Rodney Rietze, PhD, Bioprocess Innovation & Enabling Technologies, Immuno-Oncology - Novartis Institutes for Biomedical Research
Timothy Moore, Executive Vice President of Technical Operations - Kite - A Gilead Company

Lunch Briefing sponsored by Longeveron

longevron
1:00pm - 2:00pm, Wednesday 24th January
(maximum 50 attendees)

Advances in Mesenchymal Stem Cell Therapy for Chronic and Life Threatening Conditions
 

Speakers: 
Joshua M. Hare, M.D., F.A.C.C., F.A.H.A. Co-Founder & CSO, Longeveron LLC; Director & Founder, nterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine
Jeremy D. Walston, M.D., Raymond and Anna Lublin Professor of Geriatric Medicine, Johns Hopkins Asthma and Allergy Center, Johns Hopkins University
Sunjay Kaushal, M.D., Ph.D., Director, Pediatric Cardiac Surgery University of Maryland Heart & Vascular Center
Marco Pahor, M.D., Director of the University of Florida Institute on Aging, Founding Chair Department of Aging and Geriatric Research, University of Florida College of Medicine

 

Lunch Briefing with 

Miltenyi 

miltenyi biotech
1:00pm - 2:00pm, Wednesday 24th January
(Maximum 50 attendees)

Decentralized manufacturing - how blueprints can change the game

  • Big Pharma perspective: Elements of a sound manufacturing plan for commercialization
  • Consultant’s perspective: What are the common traits of developers that are prepared for commercial scale manufacturing? 
  • Short panel discussion and audience Q&A: How could a common manufacturing blueprint accelerate the transition from development to commercial scale?

 

Moderator: Dr Steven Dublin, Global Product Manager, Miltenyi Biotec
Speakers: 
Dr Anthony Davies, President, Dark Horse Consulting
Dr Oliver Bartelsen, Global Head of Business Development and Industrial Sciences, Miltenyi Biotec
Dr Bo Kara, Head Process Development, Cell & Gene Therapy Platform CMC, GlaxoSmithKline

Lunch Briefing with Saint-Gobain

saint gobain
1:00pm - 2:00pm, Wednesday 24th January
(Maximum 50 attendees)

Challenges of cell therapy automation: a perspective on disposables


Moderator: Benjamin Le Quéré, PhD, Business Director, Bioprocess Solutions, Saint-Gobain
 

 

Day 3 - Thursday

Optional lunchtime session with PCT

pct
1:00pm - 2:00pm, 25 January 2017

Cell & Gene Therapy World in summary: Highlights and trends from this year’s event


Co-Moderators: 
Sanjin Zvonic, PhD, Senior Director, Business Leader, Clinical & Commercial Manufacturing, Hitachi Chemical Advanced Therapeutics
Thomas Heathman, PhD, Business Leader, Technology Development, Manufacturing Development & GTP Services, Hitachi Chemical Advanced Therapeutics
David Smith, PhD, Biomedical Engineer, Innovation & Engineering, Hitachi Chemical Advanced Therapeutics


 

BioProcess Hub

  • Day 1 Tuesday 23: 11:00am-11:30am
  • Day 1 Tuesday 23:  3.30pm-4:00pm
  • Day 2 Wednesday 24: 11:15am - 1:00pm
  • Day 2 Wednesday 24: 3:30pm - 4:00pm
  • Day 3 Thursday 25: 10:45am - 11:15am

 

Our Partners:

dendreon cytonome thermoscientific fujifilm
chartermedical werum masthercell


Click here for more information

Supply Chain & Logistics Hub

Day 1 Tuesday 23:  1:00pm - 2:00pm 

Day 2 Wednesday 24:  2:00pm - 3:30pm

Day 3 Thursday 25:  1:00pm - 2:00pm

 

Our Partners: 

Fibrocell Trakcel worldcourier Brooks
SAVSU medcision bioservices


Click here to find out more

Sign up here

Please note:

- Only available to registered conference delegates
- Limited availability - first come first served!


 

  • "The event reflected the fantastic growing enthusiasm around cell and gene therapy, including small and large companies, investors and regulators. It was great to see everyone so engaged and so positive. The event really gives you the “pulse” of what is happening right now in cell and gene therapy."
    Anne-Virginie Eggimann,
    Vice President, Regulatory Science, Bluebird Bio, Inc
  • “Great program, great people, great venue.”
    Klaus Kühlcke
    Managing Director, EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.”
    Nathalie Clement
    Associate Director, Powell Gene Therapy Center, University of Florida
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • "It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives."
    Kurt Gielen
    Acquisition & Business Development Manager, BioMedical Materials, Chemelot Campus B.V.
  • “Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.”
    Steven Goodman
    Director, Strategy and Engagement, GSK

Past Attendees

  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • abl
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • adaptim
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • aldevron
  • allele biotech attending companies
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • apogenix
  • arthrogen
  • attending pharma/biotech companies
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • brainstorm
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • gcon
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • genvec
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • key biologics
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • longeveron
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • maxcyte
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • proqinase
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • sangamo
  •  
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • takara
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • vcls
  • attending pharma/biotech companies
  • Vineti
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • world care
  • attending pharma/biotech companies
  • attending pharma/biotech companies